About GenVec (NASDAQ:GNVC)
GenVec, Inc. (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company's development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company develops and commercializes its product candidates through collaborations. The Company's lead product candidate is CGF166. The Company's vaccine candidates include preventative vaccines against RSV and malaria, and a therapeutic vaccine for HSV. The Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:GNVC
CUSIPN/A
Phone+1-240-6320740
Debt
Debt-to-Equity RatioN/A
Current Ratio2.10%
Quick Ratio2.10%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-3,748.25%
Return on Equity-648.22%
Return on Assets-271.77%
Miscellaneous
Employees15
Outstanding Shares2,270,000
GenVec (NASDAQ:GNVC) Frequently Asked Questions
What is GenVec's stock symbol?
GenVec trades on the NASDAQ under the ticker symbol "GNVC."
When did GenVec's stock split? How did GenVec's stock split work?
GenVec's stock reverse split before market open on Thursday, December 1st 2016. The 1-10 reverse split was announced on Wednesday, November 16th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 30th 2016. An investor that had 100 shares of GenVec stock prior to the reverse split would have 10 shares after the split.
How were GenVec's earnings last quarter?
GenVec Inc (NASDAQ:GNVC) released its quarterly earnings results on Friday, November, 4th. The biopharmaceutical company reported ($0.05) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.08) by $0.03. The biopharmaceutical company had revenue of $0.17 million for the quarter, compared to analysts' expectations of $0.07 million. GenVec had a negative net margin of 3,748.25% and a negative return on equity of 648.22%. View GenVec's Earnings History.
Who are some of GenVec's key competitors?
Some companies that are related to GenVec include Apple (AAPL), Alphabet (GOOGL), Alphabet (GOOG), Amazon.com (AMZN), Microsoft (MSFT), Facebook (FB), Intel (INTC), Cisco Systems (CSCO), Comcast (CMCSA), PepsiCo (PEP), Netflix (NFLX), Nvidia (NVDA), Amgen (AMGN), Adobe Systems (ADBE), Booking (BKNG), Texas Instruments (TXN), Broadcom (AVGO) and Gilead Sciences (GILD).
Who are GenVec's key executives?
GenVec's management team includes the folowing people:
- Wayne T. Hockmeyer Ph.D., Independence Chairman of the Board
- Douglas J. Swirsky, President, Chief Executive Officer, Corporate Secretary, Director
- William N. Kelley M.D., Independent Director
- Stefan D. Loren Ph.D., Independent Director
- Quinterol J. Mallette M.D., Independent Director
- Michael S. Richman, Independent Director
- Marc R. Schneebaum, Independent Director
Has GenVec been receiving favorable news coverage?
Media coverage about GNVC stock has been trending somewhat positive this week, according to Accern. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. GenVec earned a news impact score of 0.16 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 44.54 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
How do I buy shares of GenVec?
Shares of GNVC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GenVec's stock price today?
One share of GNVC stock can currently be purchased for approximately $7.19.
How can I contact GenVec?
GenVec's mailing address is 910 Clopper Rd Ste 220n, GAITHERSBURG, MD 20878-1353, United States. The biopharmaceutical company can be reached via phone at +1-240-6320740.
MarketBeat Community Rating for GenVec (GNVC)
MarketBeat's community ratings are surveys of what our community members think about GenVec and other stocks. Vote "Outperform" if you believe GNVC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNVC will underperform the S&P 500 over the long term. You may vote once every thirty days.
GenVec (NASDAQ:GNVC) Earnings History and Estimates Chart
GenVec (NASDAQ GNVC) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/10/2017 | Q1 2017 | | ($1.88) | | $0.11 million | View | N/A |  |
| 3/6/2017 | Q4 2016 | | ($0.67) | | $0.02 million | View | N/A | |
| 11/4/2016 | Q3 2016 | ($0.0750) | ($0.05) | $0.07 million | $0.17 million | View | N/A | |
| 8/5/2016 | Q116 | ($0.10) | ($0.06) | $0.12 million | $0.03 million | View | N/A | |
| 5/12/2016 | Q1 2016 | ($0.09) | ($0.11) | $0.18 million | $0.29 million | View | N/A | |
| 3/9/2016 | Q415 | ($0.08) | ($0.10) | $0.21 million | $0.16 million | View | N/A | |
| 11/9/2015 | Q3 2015 | ($0.11) | ($0.09) | $0.15 million | $0.19 million | View | N/A | |
| 8/7/2015 | Q215 | ($0.10) | ($0.11) | $0.38 million | $0.13 million | View | N/A | |
| 5/8/2015 | Q115 | ($0.06) | ($0.09) | $0.91 million | $0.41 million | View | N/A | |
| 3/24/2015 | Q414 | $0.08 | $0.11 | $3.33 million | $3.50 million | View | Listen | |
| 11/12/2014 | Q314 | ($0.09) | ($0.10) | $1.00 million | $0.25 million | View | N/A | |
| 8/12/2014 | Q214 | ($0.15) | ($0.10) | | $0.13 million | View | N/A | |
| 5/12/2014 | Q114 | $0.04 | ($0.07) | $2.00 million | $2.10 million | View | N/A | |
| 3/28/2014 | Q413 | ($0.16) | ($0.07) | $1.52 million | $0.1450 million | View | Listen | |
| 11/12/2013 | Q313 | | ($0.23) | $2.10 million | $1.60 million | View | N/A | |
| 8/13/2013 | Q2 2013 | | ($2.40) | | $0.75 million | View | N/A | |
| 5/10/2013 | Q1 2013 | | ($2.40) | | $1.21 million | View | N/A | |
| 3/22/2013 | Q4 2012 | ($2.70) | ($2.40) | | | View | N/A | |
| 11/9/2012 | Q312 | ($0.32) | ($0.30) | $2.90 million | $2.13 million | View | N/A | |
| 8/9/2012 | Q2 2012 | ($1.40) | ($2.83) | | | View | N/A | |
| 5/10/2012 | Q1 2012 | ($1.30) | ($2.47) | | | View | N/A | |
| 3/15/2012 | Q4 2011 | ($1.40) | ($1.94) | | | View | N/A | |
| 11/9/2011 | Q3 2011 | ($0.70) | ($1.10) | | | View | N/A | |
| 8/9/2011 | Q2 2011 | ($1.90) | ($0.96) | | | View | N/A | |
| 5/9/2011 | Q1 2011 | ($1.50) | ($1.72) | | | View | N/A | |
| 3/10/2011 | Q4 2010 | ($2.00) | ($0.80) | | | View | N/A | |
| 11/8/2010 | Q3 2010 | ($3.00) | ($2.00) | | | View | N/A | |
| 8/5/2010 | Q2 2010 | ($3.00) | ($3.30) | | | View | N/A | |
| 5/6/2010 | Q1 2010 | ($3.00) | ($3.90) | | | View | N/A | |
| 3/11/2010 | Q4 2009 | ($3.00) | ($4.10) | | | View | N/A | |
| 11/5/2009 | Q3 2009 | ($4.00) | ($3.50) | | | View | N/A | |
| 8/6/2009 | Q2 2009 | ($7.00) | ($5.20) | | | View | N/A | |
| 5/7/2009 | Q1 2009 | ($6.00) | ($6.40) | | | View | N/A | |
| 3/12/2009 | Q4 2008 | ($8.00) | ($7.30) | | | View | N/A | |
| 11/6/2008 | Q3 2008 | ($7.00) | ($7.70) | | | View | N/A | |
| 8/7/2008 | Q2 2008 | ($7.00) | ($8.30) | | | View | N/A | |
| 5/8/2008 | Q1 2008 | ($6.00) | ($8.30) | | | View | N/A | |
| 3/13/2008 | Q4 2007 | ($6.00) | ($5.90) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
GenVec (NASDAQ:GNVC) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
GenVec (NASDAQ GNVC) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 8.10%
Institutional Ownership Percentage: 6.22%
GenVec (NASDAQ GNVC) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 9/16/2016 | Douglas J Swirsky | CEO | Buy | 10,000 | $0.50 | $5,000.00 | 252,500 | |
| 12/14/2015 | Douglas J Swirsky | CEO | Buy | 5,000 | $2.00 | $10,000.00 | 242,500 | |
| 11/16/2015 | Stefan Loren | Director | Buy | 4,000 | $1.93 | $7,720.00 | 5,000 | |
| 8/11/2015 | Douglas E Brough | Insider | Buy | 4,600 | $2.34 | $10,764.00 | | |
| 5/27/2014 | Ecor1 Capital, Llc | Major Shareholder | Buy | 24,140 | $2.24 | $54,073.60 | | |
| 3/28/2014 | Ecor1 Capital, Llc | Major Shareholder | Buy | 122,273 | $2.55 | $311,796.15 | | |
(Data available from 1/1/2013 forward)
GenVec (NASDAQ GNVC) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Analyzing Ligand Pharmaceuticals (LGND) and GenVec (GNVC)
www.americanbankingnews.com - February 4 at 5:10 PM |
| GenVec (GNVC) versus The Competition Financial Contrast
www.americanbankingnews.com - December 25 at 5:10 AM |
| Comparing GenVec (GNVC) & Its Rivals
www.americanbankingnews.com - December 22 at 11:32 AM |
| Reviewing GenVec (GNVC) & Its Rivals
www.americanbankingnews.com - December 21 at 7:10 PM |
| Reviewing GenVec (GNVC) & Its Peers
www.americanbankingnews.com - December 19 at 5:26 AM |
| GenVec (GNVC) and Its Rivals Head-To-Head Analysis
www.americanbankingnews.com - December 17 at 3:12 AM |
| GenVec (GNVC) vs. Its Rivals Financial Review
www.americanbankingnews.com - November 27 at 11:24 PM |
| Aptose Biosciences (APTO) & GenVec (GNVC) Financial Survey
www.americanbankingnews.com - November 14 at 1:36 PM |
| GenVec (GNVC) versus CTI BioPharma Corp. (CTIC) Critical Review
www.americanbankingnews.com - October 24 at 8:50 PM |
 | GenVec, Inc. :GNVC-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
finance.yahoo.com - October 5 at 8:13 AM |
| Intrexon Integrates Leading Adenoviral Gene Delivery Technology with Completion of GenVec Acquisition
finance.yahoo.com - October 5 at 8:13 AM |
| Reviewing Arena Pharmaceuticals (ARNA) and GenVec (GNVC)
www.americanbankingnews.com - October 4 at 12:24 AM |
| Head to Head Survey: Organovo Holdings (ONVO) and GenVec (GNVC)
www.americanbankingnews.com - August 30 at 9:12 AM |
 | Intrexon Integrates Leading Adenoviral Gene Delivery Technology with ...
www.prnewswire.com - June 17 at 10:55 PM |
 | How These Biotech Stocks are Faring? -- Pluristem Therapeutics, BioLine Rx, GenVec, and Diffusion Pharma
www.bizjournals.com - April 28 at 10:35 AM |
 | SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Files Class Action Suit Against GenVec, Inc.
feeds.benzinga.com - April 17 at 9:21 PM |
| GENVEC INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 6 at 5:07 PM |
| WeissLaw LLP: GenVec, Inc. Acquisition May Not Be in the Best Interests of GNVC Shareholders - PR Newswire (press release)
www.prnewswire.com - February 8 at 11:04 PM |
 | Rodman & Renshaw Downgrades GenVec, Inc. (GNVC) to Neutral - StreetInsider.com
www.streetinsider.com - January 26 at 6:57 PM |
 | Intrexon To Buy GenVec For $7 a Share (XON, GNVC)
www.investopedia.com - January 25 at 4:51 PM |
| Intrexon To Buy GenVec In Stock Deal For $7/Shr
www.investopedia.com - January 25 at 4:51 PM |
 | GenVec Inc. (GNVC) Is Up Sharply After Bought By Intrexon
www.rttnews.com - January 24 at 6:14 PM |
| GENVEC INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification to Rights of Securit
biz.yahoo.com - January 24 at 6:14 PM |
| East Coast biotech company licenses Washington U technology
www.bizjournals.com - January 9 at 4:18 PM |
 | GenVec Signs Option Agreement for Gene Editing and Cell Targeting Technology from Washington University in St. Louis
us.rd.yahoo.com - January 5 at 6:28 PM |
 | 8:12 am GenVec enters into an exclusive option agreement with Washington University in St. Louis to license intellectual property and technology related to gene editing and pulmonary endothelial cell targeting
us.rd.yahoo.com - January 5 at 6:28 PM |
GenVec (NASDAQ:GNVC) SEC Filings
This page is loading this company's SEC Filings. Please wait...
GenVec (NASDAQ:GNVC) Income Statement, Balance Sheet and Cash Flow Statement
GenVec (NASDAQ GNVC) Stock Chart for Monday, April, 23, 2018
Loading chart…
